Restricted accessResearch articleFirst published online 2022-02-15
Age of Symptom Onset and Longitudinal Course of Sporadic Alzheimer’s Disease,Frontotemporal Dementia,and Vascular Dementia: A Systematic Review and Meta-Analysis
Understanding how the age of dementia symptom onset affects the longitudinal course of dementia can assist with prognosis and care planning.
Objective:
To synthesize evidence regarding the relationship of age of symptom onset with the longitudinal course of sporadic Alzheimer’s disease (AD), vascular dementia (VaD), and frontotemporal dementia (FTD).
Methods:
We searched Medline, CINAHL, Embase, PsycINFO, PubMed, and Scopus for longitudinal studies that examined the impact of sporadic AD, VaD, or FTD symptom onset age on measures of cognition, function, or behavioral symptoms. Studies that examined age at diagnosis only were excluded. Quantitative meta-analysis was conducted where studies reported sufficient data for pooling.
Results:
Thirty studies met all inclusion criteria (people with AD (n = 26), FTD (n = 4)) though no studies examined VaD. Earlier onset of AD was associated with more rapid annual cognitive decline (estimate = –0.07; 95% CI –0.14 to 0.00; p = 0.045). Most studies that stratified their sample reported that younger AD onset (usually < 65 years) was associated with more rapid cognitive decline. Other evidence was inconclusive.
Conclusion:
Younger people with AD appear to have a poorer prognosis in terms of faster cognitive decline than older people with AD. More research is required to determine the impact of symptom onset age in VaD and FTD, and on functional decline in all dementias.
PrinceM, WimoA, GuerchetM, AliG-C, WuY-T, PrinaM (2015) World Alzheimer Report 2015. The global impact of dementia: An analysis of prevalence, incidence, cost and trends. Alzheimer’s Disease International, London.
2.
JarmolowiczAI, ChenH-Y, PanegyresPK (2015) The patterns of inheritance in early-onset dementia, Alzheimer’s disease and frontotemporal dementia. Am J Alzheimers Dis Other Demen30, 299–306.
3.
RossorMN, FoxNC, MummeryCJ, SchottJM, WarrenJD (2010) The diagnosis of young-onset dementia. Lancet Neurol9, 793–806.
4.
BrunnströmH, GustafsonL, PassantU, EnglundE (2009) Prevalence of dementia subtypes: A 30-year retrospective survey of neuropathological reports. Arch Gerontol Geriatr49, 146–149.
5.
CationsM, WithallA, LowL-F, DraperB (2016) What is the role of modifiable environmental and lifestyle risk factors in young onset dementia?Eur J Epidemiol31, 107–124.
6.
CationsM, WithallA, DraperB (2019) Modifiable risk factors for young onset dementia. Curr Opin Psychiatry32, 138–143.
7.
CationsM, DraperB, LowL-F, RadfordK, TrollorJ, BrodatyH, SachdevP, GonskiP, BroeGA, WithallA (2018) Non-genetic risk factors for degenerative and vascular young onset dementia: Results from the INSPIRED and KGOW studies. J Alzheimers Dis62, 1747–1758.
8.
SakaiM, HanyuH, KumeK, SatoT, HiraoK, KanetakaH, AbeS, KanayaK, SakuraiH, IwamotoT (2013) Rate of progression of Alzheimer’s disease in younger versus older patients: A longitudinal single photon emission computed tomography study. Geriatr Gerontol Int13, 555–562.
9.
FrisoniGB, TestaC, SabattoliF, BeltramelloA, SoininenH, LaaksoMP (2005) Structural correlates of early and late onset Alzheimer’s disease: Voxel based morphometric study. J Neurol Neurosurg Psychiatry76, 112–114.
10.
KoedamEL, LaufferV, van der VliesAE, van der FlierWM, ScheltensP, PijnenburgYA (2009) Early-versus late-onset Alzheimer’s disease: More than age alone. J Alzheimers Dis19, 1401–1408.
11.
DraperB, WithallA (2016) Young onset dementia. Intern Med J46, 779–786.
12.
StamouV, FontaineJL, GageH, JonesB, WilliamsP, O’MalleyM, ParkesJ, CarterJ, OyebodeJ (2021) Services for people with young onset dementia: The ‘Angela’ project national UK survey of service use and satisfaction. Int J Geriatr Psychiatry36, 411–422.
13.
LoiSM, GohAMY, WalterfangM, VelakoulisD (2020) Clinical application of findings from longitudinal studies of younger-onset dementia: Rapid review and recommendations. J Neuropsychiatry Clin Neurosci32, 322–333.
14.
GauthierS, VellasB, FarlowM, BurnD (2006) Aggressive course of disease in dementia. Alzheimers Dement2, 210–217.
15.
TschanzJT, CorcoranCD, SchwartzS, TreiberK, GreenRC, NortonMC, MielkeMM, PiercyK, SteinbergM, RabinsPV (2011) Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: The Cache County Dementia Progression study. Am J Geriatr Psychiatry19, 532–542.
16.
PanegyresPK, ChenH-Y (2013) Differences between early and late onset Alzheimer’s disease. Am J Neurodegener Dis2, 300.
17.
YoonB, ShimYS, ParkHK, ParkS, ChoiSH, YangDW (2016) Predictive factors for disease progression in patients with early-onset Alzheimer’s disease. J Alzheimers Dis49, 85–91.
18.
LaneAP, WindsorTD, AndelR, LuszczMA (2017) Is occupational complexity associated with cognitive performance or decline? Results from the Australian Longitudinal Study of Ageing. Gerontology63, 550–559.
19.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–939.
20.
BatemanRJ, AisenPS, De StrooperB, FoxNC, LemereCA, RingmanJM, SallowayS, SperlingRA, WindischM, XiongC (2011) Autosomal-dominant Alzheimer’s disease: A review and proposal for the prevention of Alzheimer’s disease. Alzheimers Res Ther3, 1–13.
21.
Critical Appraisal Skills Programme (2018) CASP Cohort Study Checklist [online]. United Kingdom.
22.
SandersonS, TattID, HigginsJ (2007) Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: A systematic review and annotated bibliography. Int J Epidemiol36, 666–676.
23.
FisherZ, TiptonE (2015) robumeta: An R-package for robust variance estimation in meta-analysis. ArXiv, Prepr ArXiv150302220.
24.
HigginsJP (2011) Cochrane handbook for systematic reviews of interventions. Version 5.1. 0 [updated March 2011]. The Cochrane Collaboration. http://www.cochrane-handb.org.
25.
HedgesLV, TiptonE, JohnsonMC (2010) Robust variance estimation in meta-regression with dependent effect size estimates. Res Synth Methods1, 39–65.
26.
BorensteinM, HigginsJP, HedgesLV, RothsteinHR (2017) Basics of meta-analysis: I2 is not an absolute measure of heterogeneity. Res Synth Methods8, 5–18.
27.
HigginsJP, ThompsonSG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med21, 1539–1558.
28.
RileyRD, HigginsJP, DeeksJJ (2011) Interpretation of random effects meta-analyses. BMJ342, d549.
29.
SterneJA, SuttonAJ, IoannidisJP, TerrinN, JonesDR, LauJ, CarpenterJ, RückerG, HarbordRM, SchmidCH (2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ343, d4002.
HuffFJ, GrowdonJH, CorkinS, RosenTJ (1987) Age at onset and rate of progression of Alzheimer’s disease. J Am Geriatr Soc35, 27–30.
33.
JacobsD, SanoM, MarderK, BellK, BylsmaF, LaflecheG, AlbertM, BrandtJ, SternY (1994) Age at onset of Alzheimer’s disease: Relation to pattern of cognitive dysfunction and rate of decline. Neurology44, 1215–1215.
34.
SternRG, MohsRC, BiererLM, SilvermanJM, SchmeidlerJ, DavidsonM, DavisKL (1992) Deterioration on the Blessed test in Alzheimer’s disease: Longitudinal data and their implications for clinical trials and identification of subtypes. Psychiatry Res42, 101–110.
35.
ZhaoQ, ZhouB, DingD, TeramukaiS, GuoQ, FukushimaM, HongZ (2014) Cognitive decline in patients with Alzheimer’s disease and its related factors in a memory clinic setting, Shanghai, China. PLoS One9, e95755.
36.
BraccoL, GallatoR, GrigolettoF, LippiA, LeporeV, BinoG, LazzaroMP, CarellaF, PiccoloT, PozzilliC (1994) Factors affecting course and survival in Alzheimer’s disease: A 9-year longitudinal study. Arch Neurol51, 1213–1219.
37.
GradyCL, HaxbyJV, HorwitzB, BergG, RapoportSI (1987) Neuropsychological and cerebral metabolic function in early vs late onset dementia of the Alzheimer type. Neuropsychologia25, 807–816.
38.
HauptM, PollmannS, KurzA (1993) Symptom progression in Alzheimer’s disease: Relation to onset age and familial aggregation: Results of a longitudinal study. Acta Neurol Scand88, 349–353.
39.
OrtofE, CrystalHA (1989) Rate of progression of Alzheimer’s disease. J Am Geriatr Soc37, 511–514.
40.
PengD, ShiZ, XuJ, ShenL, XiaoS, ZhangN, LiY, JiaoJ, WangY-J, LiuS (2016) Demographic and clinical characteristics related to cognitive decline in Alzheimer disease in China: A multicenter survey from 2011 to 2014. Medicine (Baltimore)95, e3727.
41.
SternRG, MohsRC, DavidsonM, SchmeidlerJ, SilvermanJ, Kramer-GinsbergE, SearceyT, BiererL, DavisKL (1994) A longitudinal study of Alzheimer’s disease: Measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry151, 390–396.
42.
KatzourouI, LeonenkoG, IvanovD, MeggyA, MarshallR, SimsR, WilliamsJ, HolmansP, Escott-PriceV, Alzheimer’s Disease Neuroimaging Initiative (2021) Cognitive decline in Alzheimer’s disease is not associated with APOE. J Alzheimers Dis84, 141–149.
43.
HoGJ, HansenLA, AlfordMF, FosterK, SalmonDP, GalaskoD, ThalLJ, MasliahE (2002) Age at onset is associated with disease severity in Lewy body variant and Alzheimer’s disease. Neuroreport13, 1825–1828.
44.
SinforianiE, BerniniS, PicasciaM (2019) Disease progression in relation to age at onset in a population with Alzheimer’s dementia. Aging Clin Exp Res31, 723–725.
45.
LuccaU, ComelliM, TettamantiM, TiraboschiP, SpagnoliA (1993) Rate of progression and prognostic factors in Alzheimer’s disease: A prospective study. J Am Geriatr Soc41, 45–49.
ChowTW, FridhandlerJD, BinnsMA, LeeA, MerrileesJ, RosenHJ, KetelleR, MillerBL (2012) Trajectories of behavioral disturbance in dementia. J Alzheimers Dis31, 143–149.
49.
GalaskoDR, GouldRL, AbramsonIS, SalmonDP (2000) Measuring cognitive change in a cohort of patients with Alzheimer’s disease. Stat Med19, 1421–1432.
50.
KossE, EdlandS, FillenbaumG, MohsR, ClarkC, GalaskoD, MorrisJC (1996) Clinical and neuropsychological differences between patients with earlier and later onset of Alzheimer’s disease: A CERAD analysis, Part XII. Neurology46, 136–141.
51.
WilsonRS, GilleyDW, BennettDA, BeckettLA, EvansDA (2000) Person-specific paths of cognitive decline in Alzheimer’s disease and their relation to age. Psychol Aging15, 18.
52.
OliveiraFF, ChenES, SmithMC, BertolucciPHF (2016) Predictors of cognitive and functional decline in patients with Alzheimer disease dementia from Brazil. Alzheimer Dis Assoc Disord30, 243–250.
53.
RasmussonDX, CarsonKA, BrookmeyerR, KawasC, BrandtJ (1996) Predicting rate of cognitive decline in probable Alzheimer’s disease. Brain Cogn31, 133–147.
54.
BurnsA, JacobyR, LevyR (1991) Progression of cognitive impairment in Alzheimer’s disease. J Am Geriatr Soc39, 39–45.
55.
BarnesJ, BartlettJW, WolkDA, Van Der FlierWM, FrostC (2018) Disease course varies according to age and symptom length in Alzheimer’s disease. J Alzheimers Dis64, 631–642.
CationsM, WithallA, LowL-F, RadfordK, TrollorJ, BrodatyH, SachdevP, GonskiP, BroeGA, CummingRG, DraperB (2020) Clustering and additive effects of non-genetic risk factors in non-autosomal-dominant degenerative and vascular young onset dementia. Alzheimer Dis Assoc Disord34, 128–134.
58.
ChapkoD, McCormackR, BlackC, StaffR, MurrayA (2018) Life-course determinants of cognitive reserve (CR) in cognitive aging and dementia - a systematic literature review. Aging Ment Health22, 915–926.
59.
NganduT, LehtisaloJ, SolomonA, LevälahtiE, AhtiluotoS, AntikainenR, BäckmanL, HänninenT, JulaA, LaatikainenT, LindströmJ, MangialascheF, PaajanenT, PajalaS, PeltonenM, RauramaaR, Stigsdotter-NeelyA, StrandbergT, TuomilehtoJ, SoininenH, KivipeltoM (2015) A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): A randomised controlled trial. Lancet385, 2255–2263.
60.
BlackerD, HainesJL, RodesL, TerwedowH, GoRCP, HarrellLE, PerryRT, BassettSS, ChaseG, MeyersD, AlbertMS, TanziR (1997) APOE-ɛ4 and age at onset of Alzheimer’s disease: The NIMH genetics initiative. Neurology48, 139–147.
61.
CruchagaC, Del-AguilaJL, SaefB, BlackK, FernandezMV, BuddeJ, IbanezL, DemingY, KapoorM, TostoG, MayeuxRP, HoltzmanDM, FaganAM, MorrisJC, BatemanRJ, GoateAM, HarariO (2018) Polygenic risk score of sporadic late-onset Alzheimer’s disease reveals a shared architecture with the familial and early-onset forms. Alzheimers Dement14, 205–214.
62.
LoefflerDA (2021) Modifiable, non-modifiable, and clinical factors associated with progression of Alzheimer’s disease. J Alzheimers Dis80, 1–27.
63.
BelbinO, DunnJL, LingY, MorganL, ChappellS, BeaumontH, WardenD, SmithDA, KalshekerN, MorganK (2007) Regulatory region single nucleotide polymorphisms of the apolipoprotein E gene and the rate of cognitive decline in Alzheimer’s disease. Hum Mol Genet16, 2199–2208.
64.
BallardC, PatelA, OyebodeF, WilcockG (1996) Cognitive decline in patients with Alzheimer’s disease, vascular dementia and senile dementia of Lewy body type. Age Ageing25, 209–213.
65.
JutkowitzE, MacLehoseRF, GauglerJE, DowdB, KuntzKM, KaneRL (2017) Risk factors associated with cognitive, functional, and behavioral trajectories of newly diagnosed dementia patients. J Gerontol Ser A72, 251–258.
66.
JamesBD, BennettDA (2019) Causes and patterns of dementia: An update in the era of redefining Alzheimer’s disease. Annu Rev Public Health40, 65–84.
DraperB, CationsM, WhiteF, TrollorJ, LoyC, BrodatyH, SachdevP, GonskiP, DemirkolA, CummingRG, WithallA (2016) Time to diagnosis in young-onset dementia and its determinants: The INSPIRED study. Int J Geriatr Psychiatry31, 1217–1224.
69.
LoiSM, GohAMY, MocellinR, MalpasCB, ParkerS, EratneD, FarrandS, KelsoW, EvansA, WalterfangM, VelakoulisD (2020) Time to diagnosis in younger-onset dementia and the impact of a specialist diagnostic service. Int Psychogeriatr, doi: 10.1017/S1041610220001489.
70.
LuckmannR, BigelowC (1990) Alzheimer’s disease: Age of onset and rate of progression. J Am Geriatr Soc38, 723–724.
71.
MonroeT, CarterM (2012) Using the Folstein Mini Mental State Exam (MMSE) to explore methodological issues in cognitive aging research. Eur J Ageing9, 265–274.
OlivieriP, HamelinL, LagardeJ, HahnV, Guichart-GomezE, Roué-JagotC, SarazinM (2021) Characterization of the initial complaint and care pathways prior to diagnosis in very young sporadic Alzheimer’s disease. Alzheimers Res Ther13, 90.
